- Home
- SST vs IXHL Comparison
SST vs IXHL Comparison
Compare SST & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SST | IXHL |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.7M | 49.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SST | IXHL |
|---|---|---|
| Price | $4.39 | $0.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 29.7K | ★ 24.9M |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,784,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.90 | $0.08 |
| 52 Week High | $15.00 | $2.25 |
Technical Indicators
Market Signals| Indicator | SST | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 51.14 | 57.22 |
| Support Level | $4.05 | $0.38 |
| Resistance Level | $5.00 | $0.50 |
| Average True Range (ATR) | 0.44 | 0.04 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 57.21 | 63.35 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.